Bryan Johnson's second thoughts on his longevity protocol give investors a fresh data point to weigh against the sector's promises. Apple's health business is the largest proxy for the space.
Alpha Score of 59 reflects moderate overall profile with strong momentum, poor value, strong quality, moderate sentiment.
Bryan Johnson, the tech entrepreneur whose Project Blueprint has become a symbol of the extreme antiaging movement, posted Thursday that he wonders if he went too far. The post, which came a day after he predicted humans could live to 500, gave investors in the consumer health sector a concrete reason to reexamine the aggressive claims that have fueled the sector, some investors said.
Some followers asked whether Bryan Johnson's account had been hacked. He did not delete the post or issue a correction, and did not immediately respond to a request for comment.
Johnson's doubts follow a year of unusual developments in his campaign against aging. Earlier this month, he said he had been diagnosed with gastritis, an autoimmune condition that attacks the stomach lining. The condition had gone undetected for years despite extensive testing, he said. Johnson said he planned to try to reverse what doctors consider incurable.
He also took psilocybin mushrooms twice, including a livestreamed session where he consumed nearly 5 grams of the B+ strain of Psilocybe cubensis. After analyzing the data, Johnson said the mushrooms 'offer a compelling case for longevity potential' and that they 'calmed my body and mind.'
Johnson sold the payments company Braintree in 2013 and has since poured millions of dollars a year into Blueprint. The protocol includes an early bedtime, a tightly controlled diet, daily exercise, supplements, prescription drugs, frequent bloodwork, scans, and a team of doctors. He has described himself as perhaps the most biologically measured person in history.
The question for investors is whether Johnson's second thoughts are an isolated case or a broader signal for the longevity sector, several investors said. The consumer health market Apple competes in through its Watch and Health app has grown alongside the public fascination with biohacking. Apple's health business does not depend on Johnson's personal brand. The extreme end of the market has raised consumer awareness of the category. Investors said the risk for Apple isn't direct. A shift in public sentiment around extreme antiaging from optimism to skepticism could slow adoption of premium health-tracking features, they said. Johnson's gastritis diagnosis and his experimentation with psychedelics complicate the picture. His next scheduled health update is expected in the coming weeks, though he has not confirmed a date.
Prepared with AlphaScala editorial tooling from the source reporting linked above. Indexable analysis may include a cited Alpha Score value. Publishing checks screen each story before release. Educational coverage, not personalized advice.